Publish with Us Search
Publish with Us

Targeted Cancer Therapy Connect

ISSN: 3105-3629
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Volume 2

Articles

All Articles
open-access Review Article

Published: 31 Mar 2026

Here, There, and Everywhere: Alpha-Fetoprotein in Cancer Immunotherapy

Volume 2

Alpha-fetoprotein (AFP) delivers nutrients to immature cells in a shuttle-like manner via alpha-fetoprotein receptor (AFPR)-mediated endocytosis. A small subset of immature myeloid-derived suppressor cells (MDSCs) acts as a key regulator of immune tolerance during pregnancy, cancer, and other conditions. MDSCs, low doses of AFP, and AFP-binding ligands can modulate both the innate and adaptive immune responses. MDSCs decrease excessive immune activation, while their depletion can reverse immune suppression. Reduction of..

Journal: Targeted Cancer Therapy Connect
open-access Research Article

Published: 26 Mar 2026

Association of 12q21.32 cn-LOH Affecting the KITLG p53 Response Element with Therapy Resistance in Acute Leukemia

Volume 2

Journal: Targeted Cancer Therapy Connect
open-access Perspective

Available Online: 07 May 2026

Chrono-Adaptive Resistance Disruption (CARD): A Novel Pharmacological Framework to Address Anticancer Drug Resistance

Volume 2

Drug resistance in anticancer therapy has long remained an open problem in biomedical and pharmacological research in oncology. Nevertheless, despite numerous efforts aimed at targeting biological mechanisms at the molecular and pathway levels and testing various combination therapies, the present pharmacological approach has remained largely stagnant and insensitive to changes in circadian rhythms of tumor biology and drug resistance. However, an emerging body of preclinical and clinical data suggests that..

Journal: Targeted Cancer Therapy Connect
Share
Help